Increasing evidence indicates that excessive microglial inflammasome activation contributes to neurodegeneration, and the NLRP3 inflammasome inhibition is being explored as a therapeutic strategy in conditions like Alzheimer’s and Parkinson’s disease [9,32,33,34]. Here, NLRP3 is linked to Parkinson disease.